Page 13 - Athersys Inc News Today

Dublin, Dec. 19, 2022 (GLOBE NEWSWIRE) -- The "Regenerative Medicines Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends,...

/PRNewswire/ -- Regenerative Medicine Market is projected to reach USD 40.6 billion by 2027 from USD 12.2 billion in 2022, at a CAGR of 27.2% according to a...

/PRNewswire/ -- The acute ischemic stroke (AIS) therapeutics market size is estimated to grow by USD 1,524.49 million during 2022-2027, at a CAGR of 5.72%. The...

/PRNewswire/ -- The acute ischemic stroke (AIS) therapeutics market size is estimated to grow by USD 1,524.49 million during 2022-2027, at a CAGR of 5.72%. The...

Athersys, Inc. (NASDAQ:NASDAQ:ATHX) Q3 2022 Earnings Conference Call November 15, 2022 11:00 AM ET Company Participants Ellen Gurley – Corporate Communications and Investor Relations Dan...

The Cleveland-based regenerative medicine company said a restructuring launched in the summer is 'largely completed' and is helping to control costs. Cash, though, remains a challenge, and Athersys said it will 'continue to seek strategic partnership opportunities to advance our MultiStem platform and provide non-dilutive funding.'

U.S. stocks traded lower toward the end of trading , with the Nasdaq Composite dropping 200 points on Wednesday. The Dow traded down 1.44% to 32,...

U.S. stocks traded lower midway through trading as investors focused on the outcome of the midterm elections. The Dow traded down 0.64% to 32,950...

The Cleveland-based regenerative medicine company expects to raise about $5.5 million in the offering taking place this week. Its stock price, meanwhile, continues to drop.

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) (“Athersys” or the “Company”) today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock, subject to market and other conditions, in a public offering. All o...